Diligence memo · auto-generated · as of July 2, 2026
AOA DX Inc.
AOA DX Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
AOA DX Inc. operates in Biotechnology, based in Denver, CO, USA; Cambridge, MA, USA. Blood Test for Early Detection of Ovarian Cancer
Sub-sector tags: Healthcare, Diagnostics, Women's Health.
Capital & rounds (filed)filed
AOA DX Inc. has raised $39M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $24M on 2023-07-11.
Most recent recorded round closed around 2025-10-01.
Valuation (modeled)modeled
Provath models AOA DX Inc. at approximately $34M (range $16M–$48M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.43× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 14 months.
Last raise 9 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 4.4× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 78% of Biotechnology peers (4293 compared).
Modeled value ranks above 37% of those peers.
Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.